TBV

OFG Bancorp Reports 1Q24 Results

Retrieved on: 
torsdag, april 18, 2024
Banking, Professional Services, Finance, Sale, GAAP, Pandemic, Credit, Treasury, Tangible common equity, Earthquake, Table, Conference, ETR, PPP, Digital, Retirement, Investment, TBV, Oriental Bank, EOP, FICA, Form 10-K, EPS, Acquisition, Workforce, Annual report, Government, Bank

OFG Bancorp (NYSE: OFG), the financial holding company for Oriental Bank, today reported results for the first quarter ended March 31, 2024.

Key Points: 
  • OFG Bancorp (NYSE: OFG), the financial holding company for Oriental Bank, today reported results for the first quarter ended March 31, 2024.
  • Compared to 4Q23, 1Q24 primarily reflected higher average balances and yields on investment securities, cash and loans.
  • 1Q24 included one fewer day than 4Q23, which reduced interest income by about $1.4 million.
  • A conference call to discuss 1Q24 results, outlook and related matters will be held today at 10:00 AM ET.

OFG Bancorp Reports 4Q23 & 2023 Results

Retrieved on: 
onsdag, januari 24, 2024
Banking, Professional Services, Finance, EOP, Employment, Credit, Earthquake, Tangible common equity, Sale, Delinquent, Government, Table, Form 10-K, GAAP, Investment, Pandemic, Conference, EPS, Oriental Bank, Comprehensive income, Small business, TBV, Annual report, Asset, Bank

OFG Bancorp (NYSE: OFG), the financial holding company for Oriental Bank, today reported results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • OFG Bancorp (NYSE: OFG), the financial holding company for Oriental Bank, today reported results for the fourth quarter and year ended December 31, 2023.
  • Compared to 3Q23, 4Q23 reflected annual insurance commission recognition of $2.5 million in wealth management revenues and lower mortgage servicing revenues.
  • The average balance of such wholesale funding was $602.0 million in 4Q23 compared to $266.4 million in 3Q23.
  • A conference call to discuss 4Q23 results, outlook and related matters will be held today at 10:00 AM ET.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease

Retrieved on: 
onsdag, december 20, 2023
Quality of life, MRI, Hippocampus, Hypoplastic left heart syndrome, Diffusion MRI, Neuron, Disease, Brain, Incidence, Hypersensitivity, Magnetic resonance imaging, CLEAR, Week, Mini–Mental State Examination, Dementia, Degree, Atrophy, TBV, EKG, DTI, Patient, Thalamus, Magnetic resonance, Safety, Siderosis, HLHS, Alzheimer's disease, Medical imaging

The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile.

Key Points: 
  • The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile.
  • Wa’el Hashad, CEO of Longeveron, commented: “These new data support our initial results for CLEAR MIND that we announced in October and provide further validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of mild Alzheimer’s disease.
  • In addition to these clinical findings, brain imaging showed improvement in brain architecture measured by volumetric MRI and DTI, respectively.
  • Taken together, the Company believes the results of the CLEAR MIND study build a strong foundation for further development in mild Alzheimer's disease patients.

MVB Financial Corp. Announces First Quarter 2023 Results

Retrieved on: 
torsdag, april 27, 2023
Banking, Professional Services, Finance, Core banking, Risk-weighted asset, FHLB, TCE, Current Expected Credit Losses, TBV, GAAP, Federal, Core, Sale, Compact disc, Federal Home Loan Banks, Tangibility, MVB, NIB, Investment, Risk, CECL, Capital, Growth, As a service, First Franklin Financial Corp., Chartwell, CRE, Security (finance), Mobile phone, Bank, Design, Life insurance, Airline, Pharmaceutical industry, Cryptocurrency, Fed

MVB Financial Corp. (NASDAQ: MVBF) (“MVB Financial,” “MVB” or the “Company”), the holding company for MVB Bank, Inc. ("MVB Bank"), today announced financial results for the first quarter of 2023, with reported net income of $11.3 million, or $0.90 basic and $0.87 diluted earnings per share.

Key Points: 
  • MVB Financial Corp. (NASDAQ: MVBF) (“MVB Financial,” “MVB” or the “Company”), the holding company for MVB Bank, Inc. ("MVB Bank"), today announced financial results for the first quarter of 2023, with reported net income of $11.3 million, or $0.90 basic and $0.87 diluted earnings per share.
  • See the reconciliation of TBV to its most directly comparable U.S. GAAP financial measure later in this release.
  • As previously disclosed on March 1, 2023, MVB completed the sale of its wholly-owned subsidiary, Chartwell Compliance ("Chartwell”).
  • Net charge-offs were $1.7 million for Q1 2023, compared to $5.4 million for the prior quarter.

MainStreet Bancshares, Inc., Reports Record Earnings for 1st Quarter 2023

Retrieved on: 
måndag, april 17, 2023
NIM, Insurance, Bank, Comprehensive income, Federal, Mainstreet Bank Limited, Pressure, Current Expected Credit Losses, AOCI, Washington Metro, Risk management, FDIC, TBV, Prudential, IntraFi Network, Federal Reserve, Investment, CECL, Architecture, Growth, EPS, Environment, Safety, Cryptocurrency

FAIRFAX, Va., April 17, 2023 /PRNewswire/ -- MainStreet Bancshares, Inc. (Nasdaq: MNSB & MNSBP), the holding company for MainStreet Bank, reported record net income of $8.2 million for the quarter-ended March 31, 2023.  This represents a 50% increase from the net income reported in the 1st quarter of 2022.  First-quarter results represent:

Key Points: 
  • Net interest income reached $21.1 million in the quarter ended March 31, 2023, up 38.8% from the year-earlier first quarter's $15.2 million.
  • "Implementing the Current Expected Credit Losses (CECL) accounting standard in the first quarter of 2023 resulted in a 15.6% increase in credit reserves.
  • The loan portfolio grew 14.4% to $1.62 billion as of March 31, 2023, up from $1.41 billion in the year-earlier first quarter.
  • The Company's efficiency ratio stood at 53% for the quarter ended March 31, 2023, from 55% a year earlier.

MVB Financial Corp. Announces Fourth Quarter and Full Year 2022 Results

Retrieved on: 
fredag, februari 17, 2023
Banking, Fintech, Professional Services, Finance, Integration, NIB, Core banking, TBV, Maintenance, Acquisition, Core, Risk-weighted asset, Weakness, GAAP, Sale, Paycheck Protection Program, Risk, Growth, MVB, FHLB, Depreciation, Bank, Cryptocurrency, Video game, Pension fund, Fed

Net interest income on a tax-equivalent basis totaled $33.7 million for the quarter ended December 31, 2022, up $3.6 million, or 12.0% from the quarter ended September 30, 2022 and $11.9 million, or 54.6%, from the quarter ended December 31, 2021.

Key Points: 
  • Net interest income on a tax-equivalent basis totaled $33.7 million for the quarter ended December 31, 2022, up $3.6 million, or 12.0% from the quarter ended September 30, 2022 and $11.9 million, or 54.6%, from the quarter ended December 31, 2021.
  • The tax-equivalent yield on loans was 6.1% for the quarter ended December 31, 2022, compared to 5.3% for the quarter ended September 30, 2022 and 4.6% for the quarter ended December 31, 2021.
  • The average loan-to-deposit ratio during the quarter ended December 31, 2022 was 87.7%, compared to 92.5% for the quarter ended September 30, 2022 and 74.5% for the quarter ended December 31, 2021.
  • The provision for loan losses totaled $2.7 million for the quarter ended December 31, 2022, compared to $5.1 million for the quarter ended September 30, 2022 and release of allowance of $5.7 million for the quarter ended December 31, 2021.

Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

Retrieved on: 
tisdag, januari 3, 2023
Knowledge, LVEF, Journal, Journal of Cardiovascular Translational Research, Length of stay, Patient, Mortality, Heart failure, Blood volume, TBV, Medical imaging

Oak Ridge, TN, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic pressure (PADP) monitor - two key metrics of cardiovascular congestion. Pressures, as a proxy measure, are sometimes used in guiding volume management decisions by clinicians. Data from the study demonstrated a lack of correlation between pressure measures and actual blood volume, highlighting the need for direct and 98% accurate volume measurement that the BVA-100 blood test provides.

Key Points: 
  • Pressures, as a proxy measure, are sometimes used in guiding volume management decisions by clinicians.
  • Data from the study demonstrated a lack of correlation between pressure measures and actual blood volume, highlighting the need for direct and 98% accurate volume measurement that the BVA-100 blood test provides.
  • The study titled, “Pressure-Volume Profiles in Heart Failure Across Sexes and Phenotypes,” assessed the relationship between cardiac filling pressures (a commonly used surrogate to assess blood volume) and total blood volume (TBV) measurement using Daxor’s BVA-100 blood test between sexes and left ventricular ejection fraction (LVEF), key clinical determinants of response to therapy and outcomes in heart failure.
  • “This study adds further validation that surrogate markers are not accurate for volume management compared to direct and objective measurement with blood volume analysis.

FDA Grants QT Imaging™ Clearance to Calculate Fibroglandular Volume of the Breast

Retrieved on: 
torsdag, september 22, 2022
National, Breast, Radiation, Cryotherapy, Woman, Risk, FDA, Food, Breast imaging, MM, QT, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breast cancer, CEO, TGV, Technology, Founder, FGV, Research, TBV, NIH, Medical imaging

NOVATO, Calif., Sept. 22, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV). This ratio can contribute to an assessment of risk for breast cancer and changes in this ratio can be used to measure the efficacy of medication used to treat or prevent breast cancer.

Key Points: 
  • NOVATO, Calif., Sept. 22, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV).
  • No other ultrasound-based breast imaging modality is cleared by the FDA to quantify fibroglandular volume.
  • The company has received FDA 510(K) clearance for its QT Imaging Breast Scanner.
  • The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast.

Ancora Issues Open Letter to Middlefield Banc Corp. Shareholders

Retrieved on: 
måndag, april 18, 2022
Professional Services, Finance, Board, CEO, Russell 3000 Index, Russell, SPDR, Heel, MOE, Outline, KRE, Wall Street, EPS, Organization, Sale, TBV, Growth, PPP, Company, Bank, Retirement, Cryptocurrency, Management, Risk management, Professional Services, Finance

Since our public disclosure, MBCN has returned just 9% for shareholders compared to the KRE achieving a 27% return (3x the return of MBCN) through April 11, 2022.

Key Points: 
  • Since our public disclosure, MBCN has returned just 9% for shareholders compared to the KRE achieving a 27% return (3x the return of MBCN) through April 11, 2022.
  • We viewed the succession planning process as the perfect opportunity for the Board to pursue a dual path in MBCNs go-forward strategy.
  • Instead of doing this, the Company decided to pursue its recently executed succession plan to replace longtime CEO Tom Caldwell.
  • In MBCN's June 2019 letter to Ancora, it also identified a performance peer group of Midwest banks with assets primarily ranging from $655 million to $1.5 billion.

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

Retrieved on: 
tisdag, november 16, 2021
Health, Safety, Adoption, Private Securities Litigation Reform Act, AHA, Heart failure, New Studies in Medieval History, MD, Critical care, American Heart Association, CEO, Blood volume, DXR, Blood, Technology, LVAD, Forward-looking statement, PV, Anemia, Patient, Polycythemia, GLOBE, SEC, NYSE, Diagnosis, Hematocrit, Physician, BVA, Risk, FDA, TBV, Medical device, Pharmaceutical industry, Medical imaging

Oak Ridge, TN, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test in identifying heart failure patient-specific phenotypes and detecting true anemia. These data from two separate studies were presented at the American Heart Association (AHA) Scientific Sessions virtual meeting from November 13-15, 2021.

Key Points: 
  • These data from two separate studies were presented at the American Heart Association (AHA) Scientific Sessions virtual meeting from November 13-15, 2021.
  • In heart failure, physicians seek to optimize a patients blood volume which has wide variations in total blood volume (TBV), plasma volume (PV) and red blood cell volume (RBCV).
  • This study shows that measuring with blood volume analysis (BVA) distinct phenotypes have emerged, which provides clinicians with actionable information to achieve optimal fluid management.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.